U.S. National Institutes of Health
U.S. National Institutes of Health

IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
2370123701GS-5806 in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory TractRecruitingNo Results AvailableRespiratory Syncytial VirusDrug: GS-5806|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02254408
2370223702PINS Stimulator System for Deep Brain Stimulation to Treat ObesityNot yet recruitingNo Results AvailableObesityDevice: Deep Brain Stimulationhttps://ClinicalTrials.gov/show/NCT02254395
2370323703Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart FailureNot yet recruitingNo Results AvailableDiastolic Heart FailureDevice: Adaptive servo ventilation (ASV)https://ClinicalTrials.gov/show/NCT02254382
2370423704Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy SubjectsCompletedNo Results AvailableHealthy VolunteersDrug: GC021109|Other: Placebohttps://ClinicalTrials.gov/show/NCT02254369
2370523705Zilver Flex Post-Market Study in JapanActive, not recruitingNo Results AvailablePeripheral Arterial Disease (PAD)Device: Zilver Flex Bare Metal Stenthttps://ClinicalTrials.gov/show/NCT02254356
2370623706Effects of Proximal and Distal Robot-assisted Therapy Combined With Functional TrainingRecruitingNo Results AvailableStrokeDevice: proximal robot-assisted therapy|Device: distal robot-assisted therapy|Device: combined robot-assisted therapy|Behavioral: individualized intensive therapyhttps://ClinicalTrials.gov/show/NCT02254343
2370723707ADenoVirus Initiative Study in Epidemiology in SpainRecruitingNo Results AvailableViral Conjunctivitishttps://ClinicalTrials.gov/show/NCT02254330
2370823708Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose ToleranceRecruitingNo Results AvailableImpaired Glucose ToleranceDietary Supplement: 0 mg placebo|Dietary Supplement: 300 mg GSE|Dietary Supplement: 600 mg GSE|Dietary Supplement: 900 mg GSEhttps://ClinicalTrials.gov/show/NCT02254317
2370923709Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED)RecruitingNo Results AvailableRelapsing Multiple Sclerosis|Clinically Isolated SyndromeDrug: Rebif®https://ClinicalTrials.gov/show/NCT02254304
2371023710A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 DiabetesActive, not recruitingNo Results AvailableDiabetes|Diabetes Mellitus, Type 2Drug: semaglutide|Drug: semaglutide|Drug: sitagliptinhttps://ClinicalTrials.gov/show/NCT02254291
2371123711Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal CancerRecruitingNo Results AvailableStage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Tongue CarcinomaRadiation: Intensity-Modulated Radiation Therapy|Drug: Cisplatin|Other: Quality-of-Life Assessment|Other: Laboratory Biomarker Analysishttps://ClinicalTrials.gov/show/NCT02254278
2371223712Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis SiccaActive, not recruitingNo Results AvailableKeratoconjunctivitis Sicca|Dry Eye DiseaseDrug: OTX-101 0.05%|Drug: OTX-101 0.09%|Drug: Vehiclehttps://ClinicalTrials.gov/show/NCT02254265
2371323713Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow FlowCompletedHas ResultsSlow Coronary Flow|Normal, or Near Normal Coronary Angiography|Stable AnginaDrug: Nicorandil|Drug: Nitroglycerinhttps://ClinicalTrials.gov/show/NCT02254252
2371423714Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingNo Results AvailableRecurrent Adult Hodgkin LymphomaDrug: everolimus|Drug: brentuximab vedotin|Other: pharmacological study|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT02254239
2371523715Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: Salmeterol Diskus low|Drug: Salmeterol Diskus high|Drug: Salmeterol MDI low|Drug: Salmeterol MDI highhttps://ClinicalTrials.gov/show/NCT02254226
2371623716Intra-individual Stability in Electroencephalography (EEG) ParametersCompletedNo Results AvailableStability of EEG Features in HumansOther: EEG recordinghttps://ClinicalTrials.gov/show/NCT02254213
2371723717Exercise Training and Fitness in Severe ObesityCompletedNo Results AvailableObesityOther: Fatmax group|Other: HIIT grouphttps://ClinicalTrials.gov/show/NCT02254200
2371823718Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: Salmeterol capsule - low|Drug: Salmeterol capsule - high|Drug: Salmeterol via Serevent® Diskus®https://ClinicalTrials.gov/show/NCT02254187
2371923719Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: Tiotropium/Salmeterol|Drug: Serevent® Diskus®|Drug: Spiriva®https://ClinicalTrials.gov/show/NCT02254174
2372023720Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female VolunteersTerminatedNo Results AvailableHealthyDrug: Matching placebo|Drug: BI 1181181 healthy elderly|Drug: BI 1181181 Healthy younghttps://ClinicalTrials.gov/show/NCT02254161
2372123721The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)CompletedNo Results AvailableHealthyDrug: midazolam|Drug: caffeine|Drug: digoxin|Drug: warfarin|Drug: omeprazole|Drug: BI 187004|Drug: metoprololhttps://ClinicalTrials.gov/show/NCT02254148
2372223722Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: BEA 2180 BR - rising dose|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02254135
2372323723Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: BEA 2180 BR|Drug: Placebo|Device: Respimat®https://ClinicalTrials.gov/show/NCT02254122
2372423724Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: BEA 2180 BR - rising dose|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02254109
2372523725Safety, Pharmacokinetics and Pharmacodynamics of BIRT 1696 BS in Healthy Human SubjectsCompletedNo Results AvailableHealthyDrug: BIRT 1696 BS|Drug: Placebo|Other: Grapefruit juice (GFJ)|Other: High fat meal (HFM)https://ClinicalTrials.gov/show/NCT02254096
2372623726Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male SubjectsCompletedNo Results AvailableHealthyDrug: BIBT 986 BS - low|Drug: BIBT 986 BS - high|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02254083
2372723727Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal ImpairmentCompletedNo Results AvailableHealthyDrug: BIBT 986 BShttps://ClinicalTrials.gov/show/NCT02254070
2372823728Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male SubjectsCompletedNo Results AvailableHealthyDrug: BIBT 986 BS - single rising dose|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02254057
2372923729Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or EsophagusTerminatedNo Results AvailableCarcinoma, Squamous CellDrug: bivatuzumab mertansinehttps://ClinicalTrials.gov/show/NCT02254044
2373023730Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast CancerTerminatedNo Results AvailableBreast NeoplasmsDrug: bivatuzumab mertansinehttps://ClinicalTrials.gov/show/NCT02254031

* Görseller ve İçerik tekif hakkına sahip olabilir